BioSpace News Archive

It’s time to end the stigma of mental health in the black communities and start addressing our traumas so we can work collectively, productively and fruitfully, to contribute to wealth building in our communities. Abu Simbel, LLC event company

Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the European Commission has granted conditional approval for IdefirixTM in highly sensitized kidney transplants patients.

Myomo, Inc. today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2, 2020 at 11:00 a.m. EDT.

Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 9,523,810 shares of common stock of the Company, at a price to the public of $1.05 per share, less

- Abbott’s BinaxNOW™ COVID-19 Ag Card is a rapid, reliable, highly portable, and affordable tool for detecting active coronavirus infections at massive scale - Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5% in clinical study - Abbott to offer a no-charge complementary phone app, which allows people to display their BinaxNOW test results when asked by organiz

Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2020 (FY2020). Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very pleased to report the significant corporate progress made by the Company over the last financial year. The most notable achievement was the successful FDA Advisory Committee meeting held this month which resulted in an

FDA Approves Foundation Medicine’s FoundationOne ® Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test with Multiple Companion Diagnostic Indications for Patients with Advanced Cancer FDA Approval Includes Companion Diagnostic Claims for Rubraca ® (rucaparib), the First PARP Inhibitor Approved in a Prostate Cancer Setting, and Three Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer FoundationOne Liquid CDx Analyzes More Than 300 Genes a

CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) received regulatory authorization for the manufacturing and sale of Asia’s first therapeutics app, the “CureApp SC Nicotine Addiction Treatment App and CO Checker” (hereafter, CureApp SC), from the Ministry of Health, Labour and Welfare (MHLW) on August 21st, 2020.

Understanding how cells respond to stress may provide new building blocks for designing future cancer and aging treatments, and a University of Arizona Health Sciences researcher has received a five-year, $1.6 million grant from the National Institute of General Medical Sciences to further study these implications.

Empowered by the high-end technology platform for antibody production and extensive experience in antibody development and engineering, Creative Biolabs can provide first-level neutralizing antibody (NAb) products, analytical services, and technical support.